Lilly Advances Antibody Therapy Testing

Eli Lilly & Co. (LLY) is on a fast track to develop new therapeutic medicines to fight COVID 19.  On Friday, the company announced that it will, "advance LY3127804, an investigational selective monoclonal antibody against Angiopoietin 2 (Ang2), to Phase 2 testing in pneumonia patients hospitalized with COVID-19 who are at a higher risk of progressing to acute respiratory distress syndrome (ARDS)."

Combating ARDS is very significant--as it is respiratory issues that are killing so many COVID 19 patients.  The demand for a therapy against this problem can be seen by the enormous focus on building and supplying enough ventilators.

Paul Wharton

Special thanks to Eli Lilly & Co. (LLY) for inventing the fuel of my mind